The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released new guidance for the clinical use of prostate-specific membrane antigen (PSMA)-PET imaging.
The society collaborated with the American College of Nuclear Medicine, the American Urological Association, the Australian and New Zealand Society of Nuclear Medicine, and the American Society of Clinical Oncology on the guidance, which can be found on the SNMMI's website. An autonomous and multidisciplinary PSMA PET Imaging Workgroup developed the consensus recommendations after a systematic review of existing evidence by Oregon Health Science University's Evidence-Based Practice Center, according to the SNMMI.
The new guidance comes on the heels of the National Comprehensive Cancer Network (NCCN)'s decision to update its PSMA-PET imaging guidelines.
In a statement, Telix Pharmaceuticals CEO Chief Medical Officer Dr. Colin Hayward said that the new guidance, along with the recent NCCH updated guideline, will further influence clinical practices to consider PSMA-PET imaging as an alternative to conventional bone and soft-tissue imaging for prostate cancer detection.
"These user guidelines are also important in driving private payer reimbursement, as more healthcare providers adopt PSMA PET and demonstrate its benefit to patients, in more accurate staging and diagnosis," Hayward said.
